Publications.
Cost–effectiveness of alternative NTRK testing strategies in cancer patients followed by histology-independent therapy with entrectinib: an analysis of three European countries
HEcoPerMed, personalized medicine from a health economic perspective: lessons learned and potential opportunities ahead
Budget impact and transferability of cost–effectiveness of DPYD testing in metastatic breast cancer in three health systems
Cost-Effectiveness Analysis of Treating Patients With NTRK-Positive Cancer With the Histology-Independent Therapy Entrectinib
The Net Benefit of Personalized Medicine: a Systematic Literature Review and Regression Analysis
105P prognostic value of the NTRK fusion biomarker in the Netherlands
